Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, announced today that Agrinnovation, an investment fund focused on agricultural inventions, has entered into an agreement for an investment in Cannabi-Tech Ltd., a medical cannabis company established in 2015, and based on research preformed in the laboratory of Prof. Oded Shoseyov from The Hebrew University's Robert H. Smith Faculty of Agriculture, Food and Environment.
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that RenewSense was selected to enter Brainnovation, Israel’s Brain Technologies accelerator.
RenewSenses, based on research from the lab of Professor Amir Amedi, from the Department of Medical Neurobiology at the Hebrew University of Jerusalem and the Edmond & Lily Safra Center for Brain Science, develops devices that can aid the blind and visually-disabled to navigate using other senses like sound and touch.
Yissum announced that it has signed a non-exclusive worldwide licensing agreement and a consulting agreement with Lightricks for the development and commercialization of an imaging technology that improves digital image processing. The technology, invented by Prof. Raanan Fattal from the School of Computer Science and Engineering at the Hebrew University of Jerusalem, is called “Edge Avoiding Wavelets” and it enables better and faster detail enhancement and preserves edges when sharpening digital images.
Non-invasive diagnostic test realizes the potential of circulating DNA for detection of multiple diseases
The novel technology was developed by Yinon Ben-Neriah, MD, PhD, Blumenthal Professor of Cancer Research, Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, with generous support by AMRF (The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation). Dr. Ben-Neriah and his team showed that inhibition of the clinically validated enzyme CKI-alpha induces several tumor suppressor pathways, including a new type of DNA damage response and p53 activation. This provides a novel approach to treat a wide range of cancers, in particular selective types of hematological malignancies.
Conference focusing on innovations in nanotechnology, sensors, coating materials, electronic and 3D printing, to take place on March 29 at Hebrew University Edmond J. Safra campus.
During 2015, Yissum founded a record number of eight companies based on inventions of researchers from the Hebrew University’s Center for Nanoscience and Nanotechnology.
JVP to Operate Jerusalem-based Startup Incubator for 8 Years in Partnership with Motorola Solutions, Reliance Industries and Yissum, the Research Development Company of the Hebrew University of Jerusalem
Neteera Technologies Raises 2 Million US Dollars.
Novel technology, based on electromagnetic properties of human sweat ducts, enables biometric identification along with monitoring of stress, fatigue, pain, alcohol influence, drug abuse detection, and medical diagnostics
Melodea develops environmentally-friendly, nano-crystalline cellulose based products from side streams of the paper industry
Capital to be used for completion of on-going Phase 2b study of ladostigil, for treatment of mild cognitive impairment, and preparations for pivotal Phase 3 trial
The first projects to be funded by Agrinnovation include protective coating for extension of shelf-life of fruits and vegetables, controlled release of drugs for farm animals, and invention for protection of plants via electronic means.
Results show positive trends in primary end point of delaying or preventing onset of Alzheimer’s diseaseFinal results expected in Q3 2016, following 3 years of treatment
The novel technology by Prof. Nissim Benvenisty utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs
Qlight Nanotech’s staff will remain at the Company’s site at the Hebrew University of Jerusalem, and will function as the research base for Merck for quantum-materials for the display and lighting industry
Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of advanced materials with ICL (NYSE and TASE: ICL), a global manufacturer of products based on specialty minerals that fulfill essential needs of the world’s growing population in the agriculture, processed food and engineered materials markets.
The expanded collaboration includes a research agreement involving work in the field of materials and 3D printing of Prof. Shlomo Magdassi, the Casali Institute of Applied Chemistry, the Institute of Chemistry and the Center for Nanoscience and Nanotechnology at the Hebrew University, as well as a research and license agreement for an invention in the field of solar energy by Dr. Lioz Etgar from the Institute of Chemistry at the Hebrew University.
Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission. Ikervis is approved for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. The drug was produced based on an invention by Prof. Simon Benita of the Hebrew University's Instuitute for Drug Research.
The invention to be presented at Agritech Israel 2015
The licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists, Raphael Mechoulam, Professor of medicinal chemistry, and Ruth Gallily, Professor of immunology, both from the Hebrew University; the distinguished immunologist, Professor Sir Marc Feldman, Director of the Kennedy Institute of Rheumatology; and prominent physicians and scientists at Hadassah Professors Chaim Lotan and Ronen Durst, and Dr. Lola Weiss.
Phytotech Medical went public on the Australian Securities Exchange raising AUS$5.9 million dollars
Prize awarded for contribution to collaboration between Melodea and Holmen